Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525059 | 0.82 | SIRT5 (0.56) | MAPTNPC1ALDH1A1KDM4ESIRT5 | |
| Hydrochloric Acid SCHEMBL3169871 | 0.81 | SIRT5 (0.55) | MAPTNPC1ALDH1A1KDM4ESIRT5 | |
| SCHEMBL14862178 | 0.81 | MAPT (0.61) | MAPTNPC1ALDH1A1KDM4ESIRT5 | |
| SCHEMBL18181563 | 0.81 | MAPT (0.51) | MAPTNPC1ALDH1A1RAB9AMEN1 | |
| SCHEMBL3630022 | 0.80 | RAB9A (0.56) | MAPTNPC1ALDH1A1KDM4ERAB9A | |
| SCHEMBL11363820 | 0.79 | ALDH1A1 (0.54) | MAPTNPC1ALDH1A1KDM4ERAB9A | |
| SCHEMBL22834975 | 0.77 | ALDH1A1 (0.52) | MAPTNPC1ALDH1A1KDM4ERAB9A | |
| SCHEMBL4347729 | 0.76 | NPC1 (0.48) | MAPTNPC1ALDH1A1KDM4ERAB9A | |
| SCHEMBL4347726 | 0.76 | NPC1 (0.51) | MAPTNPC1ALDH1A1KDM4ERAB9A | |
| SCHEMBL656065 | 0.74 | ALDH1A1 (0.49) | MAPTNPC1ALDH1A1KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364247-B2 | Preparation and use of novel protein kinase inhibitors | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2019-07-30 | — | — | US | disclosed |
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | BRANDEIS UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| WO-2016168992-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016168992-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364247-B2 | Preparation and use of novel protein kinase inhibitors | MAP3K20, MAP3K19, MAP3K5 | MAPT 2497/4885NPC1 3099/4885ALDH1A1 4573/4885 |
| US-20180105528-A1 | PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K5 | MAPT 2497/4885NPC1 3099/4885ALDH1A1 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.